HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
The advent of highly active antiretroviral therapy (HAART) has revolutionized the treatment of HIV. A wide variety of antiretroviral agents are now available, allowing patients and physicians a choice of effective therapy. However, drug resistance and toxicities are emerging as major treatment challenges in the HAART era. The development of agents within existing and novel antiretroviral classes remains paramount in order to preserve the reduced morbidity and mortality we have come to expect from HAART use. This article details the development of the HIV epidemic, reviewing current and future treatment strategies, and concentrating upon the viral entry inhibitors.
Jones
Rachael
R
Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, London, SW10 9NH, UK. rachaeljones30@hotmail.com
Gazzard
Brian
B
D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism; D006801:Humans
D044966:Anti-Retroviral Agents; D023581:HIV Fusion Inhibitors